How to Improve the Ability to Detect Pelvic Lymph Node Metastases of Urologic Malignancies

European Urology

Volumn 55, Issue 4, 2009, Pages 770-772

  Briganti, Alberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

BLADDER CANCER; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; EDITORIAL; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER;

CONTRAST MEDIA; DEXTRANS; DIFFUSION MAGNETIC RESONANCE IMAGING; FERROSOFERRIC OXIDE; HUMANS; LYMPHATIC METASTASIS; MALE; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; URINARY BLADDER NEOPLASMS;

EID: 60249091875     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.01.024     Document Type: Editorial

References (20)

1. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
2. Dhar N.B., Klein E.A., Reuther A.M., Thalmann G.N., Madersbacher S., and Studer U.E. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol 179 (2008) 873-878
3. Masterson T.A., Bianco Jr. F.J., Vickers A.J., et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 175 (2006) 1320-1324
4. Joslyn S.A., and Konety B.R. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 68 (2006) 121-125
5. DiMarco D.S., Zincke H., Sebo T.J., Slezak J., Bergstralh E.J., and Blute M.L. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 173 (2005) 1121-1125
6. Cagiannos I., Karakiewicz P., Eastham J.A., et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 170 (2003) 1798-1803
7. Briganti A., Chun F.K.-H., Salonia A., et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 49 (2006) 1019-1027
8. Burkhard F.C., Schumacher M.C., and Studer U.E. An extended pelvic lymph-node dissection should be performed in most patients if radical prostatectomy is truly indicated. Nat Clin Pract Urol 3 (2006) 454-455
9. Heidenreich A., Varga Z., and Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167 (2002) 1681-1686
10. Briganti A., Chun F.K.-H., Salonia A., et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 50 (2006) 1006-1013
11. Schumacher M.C., Burkhard F.C., Thalmann G.N., Fleischmann A., and Studer U.E. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54 (2008) 344-352
12. Briganti A., Karnes J.R., Da Pozzo L.F., et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55 (2009) 261-270
13. Wolf Jr. J.S., Cher M., Dall'era M., Presti Jr. J.C., Hricak H., and Carroll P.R. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 153 (1995) 993-999
14. Katz S., and Rosen M. MR imaging and MR spectroscopy in prostate cancer. management. Radiol Clin North Am 44 (2006) 723-734
15. 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 54 (2008) 392-401
16. Mattei A., Fuechsel F.G., Bhatta Dhar N., et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 53 (2008) 118-125
17. Bellin M.F., Roy C., Kinkel K., et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles-initial clinical experience. Radiology 207 (1998) 799-808
18. Harisinghani M.G., Barentsz J., Hahn P.F., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348 (2003) 2491-2499
19. Heesakkers R.A., Hövels A.M., Jager G.J., et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 9 (2008) 850-856
20. Thoeny H.C., Triantafyllou M., Birkhaeuser F.D., et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 55 (2009) 761-769